Pharmaxis (OTCMKTS:PXSLY) vs. Graybug Vision (NASDAQ:GRAY) Critical Survey

Risk & Volatility

Pharmaxis has a beta of 1.22, indicating that its stock price is 22% more volatile than the S&P 500. Comparatively, Graybug Vision has a beta of 1.2, indicating that its stock price is 20% more volatile than the S&P 500.

Profitability

This table compares Pharmaxis and Graybug Vision’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pharmaxis	N/A	N/A	N/A
Graybug Vision	N/A	-77.61%	-71.34%

Insider and Institutional Ownership

49.9% of Graybug Vision shares are held by institutional investors. 7.9% of Graybug Vision shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Pharmaxis and Graybug Vision”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharmaxis	$8.75 million	3.03	-$9.36 million	N/A	N/A
Graybug Vision	$426.96 million	0.00	-$35.60 million	($24.23)	-0.03

Pharmaxis has higher earnings, but lower revenue than Graybug Vision.

Summary

Pharmaxis beats Graybug Vision on 5 of the 8 factors compared between the two stocks.

About Pharmaxis

Pharmaxis Ltd engages in the research, development, and commercialization of healthcare products for the treatment of fibrotic and inflammatory diseases worldwide. The company operates through two segments, Mannitol business, and New Drug Development. It offers Bronchitol, an inhaled dry powder for the treatment of cystic fibrosis; and Aridol, an airways inflammation test that is used to identify twitchy or hyper-responsive airways, as well as to assist in diagnosing and managing asthma. The company's product pipeline consists of amine oxidase inhibitors comprising semicarbazide-sensitive amine oxidase for diabetic retinopathy; selective lysyl oxidase like inhibitors targeting chronic fibrotic diseases, such as NASH, pulmonary fibrosis, kidney fibrosis, and cardiac fibrosis; and pan-lysyl oxidase inhibitors targeting severe fibrotic indications, which includes cancers and scarring. It is also developing Orbital, a dry powder inhaler to deliver high drug doses to lungs. Pharmaxis Ltd was founded in 1998 and is headquartered in Frenchs Forest, Australia.

About Graybug Vision

Graybug Vision, Inc., a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. It also develops GB-102, for the treatment of diabetic retinopathy; and GB-401, an intravitreally injected implant formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc. was incorporated in 2011 and is based in Redwood City, California.